Trial Profile

Effect of Alemtuzumab treatment on the peripheral immune repertoire in multiple sclerosis patients

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 02 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alemtuzumab (Primary)
Indications Multiple sclerosis
Focus Adverse reactions; Pharmacokinetics

Most Recent Events

26 Apr 2022 Results employing longitudinal peripheral immune repertoire analysis of multiple sclerosis (MS) patients pre- and post-Alemtuzumab treatment to understand better the beneficial properties and potential side effects presented at the 74th Annual Meeting of the American Academy of Neurology 2022
01 May 2020 Results presented at the 72nd Annual Meeting of the American Academy of Neurology
22 Jan 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com